Journal article

Three Paths to Drug Discovery in Psychiatry

Michael Berk, Andrew A Nierenberg

American Journal of Psychiatry | AMER PSYCHIATRIC PUBLISHING, INC | Published : 2015

University of Melbourne Researchers

Grants

Awarded by National Health and Medical Research Council


Funding Acknowledgements

Professor Berk has received research support from or served as a speaker or consultant for AstraZeneca, Beyond Blue, Bioadvantex, Bristol-Myers Squibb, Cancer Council of Victoria, Cooperative Research Centre, Eli Lilly, Geelong Medical Research Foundation, GlaxoSmithKline, Janssen-Cilag, Lundbeck, MBF, Mayne Pharma, Meat and Livestock Board, Merck, National Health and Medical Research Council, NIH, Organon, Novartis, Pfizer, Rotary Health, Servier, Sanofi Synthelabo, Servier, Simons Autism Foundation, Solvay, Stanley Medical Research Foundation, Woolworths, and Wyeth; he is supported by National Health and Medical Research Council Senior Principal Research Fellowship 1059660.Dr. Nierenberg has received grant support or honoraria from or served as a consultant to Agency for Healthcare Research and Quality, American Foundation for Suicide Prevention, AstraZeneca, Belvoir Publications, Brain and Behavior Research Foundation, Brain Cells, Bristol-Myers Squibb, Corcept, Eli Lilly, Forest, Genentech, GlaxoSmithKline, Hoffman LaRoche, Marriott Foundation, MedAvante, Merck, Methylation Sciences, Naurex, NIMH, Pamlab, Patient-Centered Outcomes Research Institute, Pfizer, Ridge Diagnostics, Slack Publications, Sunovion, Takeda/Lundbeck, and Teva; he owns stock options in Appliance Computing (Mindsite), Brain Cells, and MedAvante; income is possible from Infomedic.com, but no revenue has been received to date; through Massachusetts General Hospital (MGH), he is named for copyrights to the Clinical Positive Affect Scale and the MGH Structured Clinical Interview for the Montgomery-Asberg Depression Rating Scale, exclusively licensed to the MGH Clinical Trials Network and Institute